MannKind Corporation (MannKind), a biopharmaceutical company, focuses on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases.
The…
Analysis
Middle-of-the-road
MannKind Corporation sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
Valuation data is not available for this company.
Growth is tepid; the safety picture is fragile. The company scores 6/20 on our value-creation score: not creating value.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202692
100
2026
All-time high
100
Jun 2026
All-time low
92
Mar 2026
Average rank
96
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
77
—
—
—
Price/Earnings
21
—
—
—
Price/Book
95
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
78
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.